Things Worth Noting
A phase III trial presented at ESMO 2025 shows that combining enzalutamide with hormone therapy (ADT) cuts the risk of death by over 40% in men with advanced prostate cancer that returns after surgery or radiation. The EMBARK trial, involving 1,068 men, tested enzalutamide plus leuprolide, leuprolide alone, or enzalutamide monotherapy in high-risk, biochemically recurrent […]
Amygdalin, often called Vitamin B17 or Laetrile, is a compound in apricot kernels and peach pits, promoted as an alternative cancer treatment. This cyanogenic glycoside releases cyanide in the body, which some claim targets cancer cells, inducing apoptosis. However, clinical trials, like those by the National Cancer Institute, show no antitumor benefits, and the FDA […]
EBC-46, or tigilanol tiglate, is a promising anticancer compound derived from the seeds of the Blushwood tree in Queensland, Australia. This diterpene ester, discovered by QBiotics, activates protein kinase C to trigger tumor cell death and local inflammation, boosting immune response. Administered via direct injection, it effectively targets solid tumors like melanoma and breast cancer. […]